Headache and Migraine

The professor of neurology at the University of Vermont Larner College of Medicine and founding president of the Alliance for Headache Disorders Advocacy discussed the special article he and colleagues published in the Headache journal on migraine care.

Migraine expert Teshamae Monteith, MD, describes how the University of Miami's inpatient migraine service has been a go-to resource for migraine help.

The CEO of Biohaven Pharmaceuticals discussed the company’s new collaboration, which has made rimegepant (Nurtec ODT) available for prescription through Cove’s telemedicine platform.

The professor of neurology at the University of Vermont Larner College of Medicine and founding president of the Alliance for Headache Disorders Advocacy discussed the need to get patients with migraine access to medications during the COVID-19 pandemic.

Biohaven Pharmaceutical’s oral acute migraine agent rimegepant (Nurtec ODT) is the first branded medication available through Cove’s platform, which provides consults with independent health care providers and access to prescriptions.

In addition to having a lowered number of headache days, around 20% of patients transformed to low-frequency, episodic migraine on follow-up.

The professor of neurology at the University of Vermont Larner College of Medicine and founding president of the Alliance for Headache Disorders Advocacy spoke about the impact the COVID-19 pandemic has had on his practice.

Incorporating remote electrical neuromodulation into the standard of care may have a positive impact on migraine management by reducing the reliance on acute medications.

The assistant professor of Neurology, Concussion and Headache Medicine divisions, Mayo Clinic, Scottsdale, Arizona discussed the evolving migraine treatment landscape and how they have been incorporated into her practice.

Results from one of the first multi-case studies of neurologic manifestations of COVID-19 demonstrate complex CNS involvement and raise further questions about pathological mechanism.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 10, 2020.

Mayo Clinic has provided advice to lower stress and anxiety amidst the COVID-19 pandemic.

Eligible commercially insured patients may pay as little as $5 per infusion every 3 months for eptinezumab through the VYEPTI Copay Assistance Program, according to Lundbeck.

Phase 3 INTERCEPT data suggest the agent is successful in migraine treatment, and an NDA submission of AXS-07 in the acute treatment of migraine is on track for Q4 2020.

Patients with migraine may order the pain relief medication device directly to their homes through UpScript’s telemedicine platform.

Neurology News Network for the week ending April 4, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 3, 2020.

What happens to the approximately 24% of pediatric patients with migraine who do not respond to the preventive treatments recommended in the AAN guidelines?

The PROMISE-2 clinical trial data suggest that the recently approved, IV-administered eptinezumab (Vyepti; Lundbeck) is effective in both 100- and 300-mg doses for patients with chronic migraine.

Mayo Clinic is in the forefront of changing practice techniques during the COVID-19 pandemic by using video appointments to reach patients.

NeurologyLive’s parent company, MJH Life Sciences, will be hosting the virtual MJH Life Sciences Sleeves Up Blood Drive from March 31 through April 30.

Researchers noted at least a 50% reduction from baseline in mean number of moderate to severe migraine days per month in 48% of the rimegepant group.

After meeting co-primary end points of pain freedom and freedom from the most bothersome symptom, the acute migraine agent has been cleared for a phase 3 trial by the FDA.

"Mind Moments," a podcast from NeurologyLive, brings you exclusive interviews with Barry A. Singer, MD, and Nina Riggins, MD, PhD.

Eton Pharmaceuticals plans to submit a new drug application for ET-101 in the third quarter of 2020, anticipating its formulation to be the first approved oral topiramate solution.